Cargando…
The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial
BACKGROUND: Dementia is a large and growing health care burden globally, and its major cause is Alzheimer's disease (AD). MLC901 (Neuroaid II) is a simplified form of MLC601 (Neuroaid), a Traditional Chinese Medicine with neuroprotective and neuroproliferative properties in cellular and animal...
Autores principales: | Chen, Christopher L.H., Sharma, Purabi Reang, Tan, Boon Yeow, Low, Casuarine, Venketasubramanian, Narayanaswamy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352850/ https://www.ncbi.nlm.nih.gov/pubmed/30723778 http://dx.doi.org/10.1016/j.trci.2018.12.001 |
Ejemplares similares
-
Safety and Use of MLC601/MLC901 (NeuroAiD(TM)) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry
por: Kumar, Ramesh, et al.
Publicado: (2020) -
NEURoaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo‐controlled randomized trial
por: Chen, Christopher L. H., et al.
Publicado: (2021) -
MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial
por: Theadom, A., et al.
Publicado: (2018) -
The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients
por: Navarro, Jose C., et al.
Publicado: (2012) -
The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD)
por: Venketasubramanian, Narayanaswamy, et al.
Publicado: (2015)